ANG Lifesciences India (Small Cap - Next Multibagger) Share Target 2025, 2026 To 2035
|
ANG Lifesciences India Limited |
|||
|
Price: ₹44.75 (-1.63%) | ||
| 52 Week Low: ₹42.02 52 Week High: ₹86.06 |
|||
| Market Capital: 23.28 Crore (Smallcap) | |||
| -> | |||
Show Table of Contents
Table of Contents
- 1: Approach 1: Technical Analysis Paired With Price Action
- 1.1: ANG Lifesciences India Share Price Target For 2025
- 1.1.1: ANG Lifesciences India Share Price Target Table For 2025
- 1.1.2: Short-Term Technical Outlook
- 1.2: ANG Lifesciences India Share Price Target For 2026
- 1.2.1: ANG Lifesciences India Share Price Target Table For 2026
- 1.2.2: Long-Term Technical Outlook
- 2: Approach 2: Machine Learning By Studying Historical Prices
- 2.1: ANG Lifesciences India Share Price Target Chart and Table From 2025, 2026, 2027 to 2035
- 3: ANG Lifesciences India Financial Performance
- 3.0.1: Is ANG Lifesciences India A Good Buy For Long Term?
To predict the ANG Lifesciences India's future market prices, we harnessed 2 dynamic approaches:
Approach 1: Technical Analysis Paired With Price Action
Approach 2: Machine Learning By Studying Historical Prices
Approach 1: Technical Analysis Paired With Price Action
ANG Lifesciences India Share Price Target For 2025
The line chart displays the monthly closing prices of ANG Lifesciences India with a black line. The green line shows three potential target prices for 2025, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for ANG Lifesciences India shares in 2025, see the table below.
ANG Lifesciences India Share Price Target Table For 2025
| Level | Value | Analysis |
|---|---|---|
| 2025 Target 3 | 49.98 (+11.68%) | Price Action: Dec 2024 High |
| 2025 Target 2 | 49.45 (+10.5%) | Technical Indicator: MA150 |
| 2025 Target 1 | 48.82 (+9.09%) | Price Action: 14 Oct 2024 Low |
| Current Price | 44.75 | ANG Lifesciences India's share price as of 02 Jan 2025 |
| Stop Loss 1 | 43.71 (-2.33%) | Price Action: 21 Nov 2024 Low |
| Stop Loss 2 | 43.2 (-3.47%) | Price Action: Jan 2020 High |
| Stop Loss 3 | 42.7 (-4.59%) | Price Action: Sep 2020 Low |
Short-Term Technical Outlook
Current Technical Position: ANG Lifesciences India is displaying bearish momentum trading below key moving averages.
Key Technical Level: The 50-day moving average at ₹45.97 serves as the nearest technical reference point.
Historical Returns: 3-month: -3.91% | 6-month: -12.24% | 1-year: -36.86%
ANG Lifesciences India Share Price Target For 2026
The line chart displays the monthly closing prices of ANG Lifesciences India with a black line. The green line shows three potential target prices for 2026, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for ANG Lifesciences India shares in 2026, see the table below.
ANG Lifesciences India Share Price Target Table For 2026
| Level | Value | Analysis |
|---|---|---|
| 2026 Target 3 | 95.44 (+113.27%) | Price Action: Chart |
| 2026 Target 2 | 93.66 (+109.29%) | Price Action: Chart |
| 2026 Target 1 | 92.73 (+107.21%) | Fibonacci Extension Level 64.90% |
| Current Price | 44.75 | ANG Lifesciences India's share price as of 02 Jan 2025 |
| Stop Loss 1 | 33.84 (-24.38%) | Price Action: Chart |
| Stop Loss 2 | 33.5 (-25.14%) | Price Action: Chart |
| Stop Loss 3 | 32.9 (-26.49%) | Price Action: Chart |
Long-Term Technical Outlook
52-Week Range Analysis: ANG Lifesciences India is currently trading near its 52-week low of ₹42.02, indicating potential value opportunity.
Long-Term Trend Analysis: The stock is in a bearish long-term trend, trading below key long-term moving averages.
Long-Term Performance: 1-year: -36.86% | 3-year: -81.83% | 5-year: +160.02%
Stay ahead of the market! Get instant alerts on crucial market breakouts. Don't miss out on key opportunities!
Your phone number will be HIDDEN to other users.
Approach 2: Machine Learning By Studying Historical Prices
ANG Lifesciences India Share Price Target Chart and Table From 2025, 2026, 2027 to 2035
| Year | Target 1 | Target 1 YoY Chg % | Target 2 |
|---|---|---|---|
| Current Price | ₹44.75 | ||
| 2025 | ₹46.35 | +3.57% | ₹47.05 |
| 2026 | ₹52.82 | +13.95% | ₹53.61 |
| 2027 | ₹63.69 | +20.57% | ₹64.65 |
| 2028 | ₹70.66 | +10.94% | ₹71.72 |
| 2029 | ₹94.79 | +34.14% | ₹96.21 |
| 2030 | ₹106.03 | +11.85% | ₹107.62 |
| 2031 | ₹107.62 | +1.49% | ₹109.23 |
| 2032 | ₹96.24 | -10.57% | ₹97.68 |
| 2033 | ₹87.74 | -8.83% | ₹89.06 |
| 2034 | ₹84.79 | -3.36% | ₹86.06 |
| 2035 | ₹87.23 | +2.87% | ₹88.54 |
Note: Target 1 and Target 2 represent price levels that the stock is most likely to achieve during the respective year, based on machine learning algorithms analyzing historical price patterns and market behavior. These predictions are generated through comprehensive analysis of the stock's historical data using advanced ML models.
ANG Lifesciences India Financial Performance
| Metric | Value | Description |
|---|---|---|
| Market Capital | 23.28 Crore | Market valuation of ANG Lifesciences India's shares. |
| Revenue (TTM) | 146.1 Crore | Total revenue generated by ANG Lifesciences India over the past twelve months. |
| Net Income (TTM) | -10.14 Crore | Net Profit or Loss after all the expenses over the past twelve months. |
| Operating Margin | +0.16% | Income from operations as a percentage of revenue, before taxes and interest. |
| Profit Margin | +34.9% | Net income as a percentage of revenue, after all expenses. |
| Revenue Growth (Quarterly) |
-51.35% | Change in revenue compared to the previous quarter. |
| Debt-to-Equity (D/E) Ratio |
0.95 | Company's total debt divided by total shareholder equity. |
| Total Debt | 72.83 Crore | Sum of ANG Lifesciences India's current & long-term financial obligations. |
Is ANG Lifesciences India A Good Buy For Long Term?
ANG Lifesciences India, a small-cap stock with a market capitalization of ₹23.28 crore, presents a risky long-term investment. While revenue reached ₹146.1 crore in the last twelve months (TTM), a net loss of ₹10.14 crore and substantial debt of ₹72.83 crore (Q1 2024-25) raise significant concerns. Negative returns over the past 3 months (-9.77%), 6 months (-19.29%), 12 months (-34.28%), and YTD (-33.72%) further highlight the stock's poor performance. Despite a positive 5-year return (17.97%), the current financial health and recent performance suggest it's not a good buy for long-term investors.
Disclaimer: The information provided on this page is for educational purposes only and should not be considered as financial advice. Historical performance data and technical analysis cannot guarantee future results. Stock investments are subject to market risks. Please consult with a qualified financial advisor before making any investment decisions.
All stock data shown is sourced from publicly available information and while we strive for accuracy, we cannot guarantee the absolute accuracy of all figures. Users should verify critical information from official sources before making investment decisions.
